Disease relapse after neoadjuvant cisplatin, methotrexate and vinblastine (CMV) chemotherapy plus radical cystectomy in locally advanced bladder cancer

T. Torelli, P. Corrada, B. Campo

Research output: Contribution to journalArticlepeer-review

Abstract

From 1986 until today 32 patients with metastatic bladder cancer were treated by Cisplatin, Methotrexate and Vinblastine (CMV) chemotherapy. We divided these patients into three groups: 13 patients with disease relapse after neoadjuvant CMV chemotherapy and radical cystectomy (group A); 11 pts with disease relapse after radical cystectomy alone (group B) and 8 pts. with metastatic bladder cancer as first clinical observation and not surgically pretreated (group C). We performed a total of 88 cycles, in accordance with Harker's schedule, because 8 pts. stopped chemotherapy for heavy toxicity(2 deaths). Median survival was 9.8 months in group A, 16.9 months in group B and 6.3 months in group C. In our opinion, the efficacy of chemotherapy is greater in patients who have never undergone this treatment before than in those where a neoadjuvant therapy has been performed. Probably it depends upon the heavy cumulative toxicity and selection of chemoresistant cellular clones.

Original languageEnglish
Pages (from-to)109-111
Number of pages3
JournalActa Urologica Italica
Volume12
Issue number2
Publication statusPublished - 1998

Keywords

  • Bladder cancer
  • Chemotherapy
  • Metastasis

ASJC Scopus subject areas

  • Urology

Fingerprint

Dive into the research topics of 'Disease relapse after neoadjuvant cisplatin, methotrexate and vinblastine (CMV) chemotherapy plus radical cystectomy in locally advanced bladder cancer'. Together they form a unique fingerprint.

Cite this